Literature DB >> 12169576

Iron regulates xanthine oxidase activity in the lung.

Andrew J Ghio1, Thomas P Kennedy, Jacqueline Stonehuerner, Jacqueline D Carter, Kelly A Skinner, Dale A Parks, John R Hoidal.   

Abstract

The iron chelator deferoxamine has been reported to inhibit both xanthine oxidase (XO) and xanthine dehydrogenase activity, but the relationship of this effect to the availability of iron in the cellular and tissue environment remains unexplored. XO and total xanthine oxidoreductase activity in cultured V79 cells was increased with exposure to ferric ammonium sulfate and inhibited by deferoxamine. Lung XO and total xanthine oxidoreductase activities were reduced in rats fed an iron-depleted diet and increased in rats supplemented with iron, without change in the ratio of XO to total oxidoreductase. Intratracheal injection of an iron salt or silica-iron, but not aluminum salts or silica-zinc, significantly increased rat lung XO and total xanthine oxidoreductase activities, immunoreactive xanthine oxidoreductase, and the concentration of urate in bronchoalveolar fluid. These results suggest the possibility that the production of uric acid, a major chelator of iron in extracellular fluid, is directly influenced by iron-mediated regulation of the expression and/or activity of its enzymatic source, xanthine oxidase.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12169576     DOI: 10.1152/ajplung.00413.2000

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  9 in total

1.  Lipid-derived free radical production in superantigen-induced interstitial pneumonia.

Authors:  Hisako Miyakawa; Ronald P Mason; Jinjie Jiang; Maria B Kadiiska
Journal:  Free Radic Biol Med       Date:  2009-04-17       Impact factor: 7.376

Review 2.  Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol.

Authors:  Pál Pacher; Alex Nivorozhkin; Csaba Szabó
Journal:  Pharmacol Rev       Date:  2006-03       Impact factor: 25.468

3.  Could uric acid be a modifiable risk factor in subjects with pulmonary hypertension?

Authors:  Sergey I Zharikov; Erik R Swenson; Miguel Lanaspa; Edward R Block; Jawaharlal M Patel; Richard J Johnson
Journal:  Med Hypotheses       Date:  2010-01-12       Impact factor: 1.538

4.  Markers of Iron Status Are Associated with Risk of Hyperuricemia among Chinese Adults: Nationwide Population-Based Study.

Authors:  Xiangping Li; Tingchao He; Kai Yu; Qian Lu; Rashad Alkasir; Guifang Guo; Yong Xue
Journal:  Nutrients       Date:  2018-02-09       Impact factor: 5.717

5.  The relationship between ferritin and urate levels and risk of gout.

Authors:  Tahzeeb Fatima; Cushla McKinney; Tanya J Major; Lisa K Stamp; Nicola Dalbeth; Cory Iverson; Tony R Merriman; Jeffrey N Miner
Journal:  Arthritis Res Ther       Date:  2018-08-15       Impact factor: 5.156

Review 6.  The Role of Oxidative Stress in Hyperuricemia and Xanthine Oxidoreductase (XOR) Inhibitors.

Authors:  Ning Liu; Hu Xu; Qianqian Sun; Xiaojuan Yu; Wentong Chen; Hongquan Wei; Jie Jiang; Youzhi Xu; Wenjie Lu
Journal:  Oxid Med Cell Longev       Date:  2021-03-26       Impact factor: 6.543

7.  Association between serum urate and CSF markers of Alzheimer's disease pathology in a population-based sample of 70-year-olds.

Authors:  Tahzeeb Fatima; Lennart T H Jacobsson; Silke Kern; Anna Zettergren; Kaj Blennow; Henrik Zetterberg; Lena Johansson; Mats Dehlin; Ingmar Skoog
Journal:  Alzheimers Dement (Amst)       Date:  2021-12-08

Review 8.  Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview.

Authors:  Changyi Chen; Jian-Ming Lü; Qizhi Yao
Journal:  Med Sci Monit       Date:  2016-07-17

9.  Regulation of xanthine dehydrogensase gene expression and uric acid production in human airway epithelial cells.

Authors:  Ryan D Huff; Alan C-Y Hsu; Kristy S Nichol; Bernadette Jones; Darryl A Knight; Peter A B Wark; Philip M Hansbro; Jeremy A Hirota
Journal:  PLoS One       Date:  2017-09-01       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.